SciELO - Scientific Electronic Library Online

SciELO - Scientific Electronic Library Online

Article References

FORD, Nathan et al. Chronic hepatitis C treatment outcomes in low- and middle-income countries: a systematic review and meta-analysis. Bull World Health Organ [online]. 2012, vol.90, n.7, pp.540-550. ISSN 0042-9686.

    1. Hadigan C, Kottilil S. Hepatitis C virus infection and coinfection with human immunodeficiency virus: challenges and advancements in management. JAMA 2011;306:294-301. doi:10.1001/jama.2011.975 PMID:21771990 [ Links ]

    2. Shepard CW, Finelli L, Alter MJ. Global epidemiology of hepatitis C virus infection. Lancet Infect Dis 2005;5:558-67. doi:10.1016/S1473-3099(05)70216-4 PMID:16122679 [ Links ]

    3. Viral hepatitis: global policy. London: World Hepatitis Alliance; 2011. Available from:[accessed 12 January 2012] [ Links ]

    4. Viral hepatitis. WHA63.18. Sixty-third World Health Assembly. Agenda item 11.12. Geneva: World Health Organization; 2010. Available from:[accessed 12 January 2012] [ Links ]

    5. Amin J, Law MG, Bartlett M, Kaldor JM, Dore GJ. Causes of death after diagnosis of hepatitis B or hepatitis C infection: a large community-based linkage study. Lancet 2006;368:938-45. doi:10.1016/S0140-6736(06)69374-4 PMID:16962883 [ Links ]

    6. Duberg AS, Torner A, Davidsdottir L, Aleman S, Blaxhult A, Svensson A et al. Cause of death in individuals with chronic HBV and/or HCV infection, a nationwide community-based register study. J Viral Hepat 2008;15:538-50. doi:10.1111/j.1365-2893.2008.00982.x PMID:18397223 [ Links ]

    7. McDonald SA, Hutchinson SJ, Bird SM, Mills PR, Dillon J, Bloor M et al. A population-based record linkage study of mortality in hepatitis C-diagnosed persons with or without HIV coinfection in Scotland. Stat Methods Med Res 2009;18:271-83. doi:10.1177/0962280208094690 PMID:19036907 [ Links ]

    8. John-Baptiste A, Krahn M, Heathcote J, Laporte A, Tomlinson G. The natural history of hepatitis C infection acquired through injection drug use: meta-analysis and meta-regression. J Hepatol 2010;53:245-51. doi:10.1016/j.jhep.2010.03.015 PMID:20537752 [ Links ]

    9. Massard J, Ratziu V, Thabut D, Moussalli J, Lebray P, Benhamou Y et al. Natural history and predictors of disease severity in chronic hepatitis C. J Hepatol 2006;44(Suppl):S19-24. doi:10.1016/j.jhep.2005.11.009 PMID:16356583 [ Links ]

    10. Chen SL, Morgan TR. The natural history of hepatitis C virus (HCV) infection. Int J Med Sci 2006;3:47-52. doi:10.7150/ijms.3.47 PMID:16614742 [ Links ]

    11. Ghany MG, Strader DB, Thomas DL, Seeff LB. Diagnosis, management, and treatment of hepatitis C: an update. Hepatology 2009;49:1335-74. doi:10.1002/hep.22759 PMID:19330875 [ Links ]

    12. Thein HH, Yi Q, Dore GJ, Krahn MD. Estimation of stage-specific fibrosis progression rates in chronic hepatitis C virus infection: a meta-analysis and meta-regression. Hepatology 2008;48:418-31. doi:10.1002/hep.22375 PMID:18563841 [ Links ]

    13. Pearlman BL, Traub N. Sustained virologic response to antiviral therapy for chronic hepatitis C virus infection: a cure and so much more. Clin Infect Dis 2011;52:889-900. doi:10.1093/cid/cir076 PMID:21427396 [ Links ]

    14. Cooper CL, Mills E, Wabwire BO, Ford N, Olupot-Olupot P. Chronic viral hepatitis may diminish the gains of HIV antiretroviral therapy in sub-Saharan Africa. Int J Infect Dis 2009;13:302-6. doi:10.1016/j.ijid.2008.06.042 PMID:19004656 [ Links ]

    15. Operskalski EA, Kovacs A. HIV/HCV co-infection: pathogenesis, clinical complications, treatment, and new therapeutic technologies. Curr HIV/AIDS Rep 2011;8:12-22. doi:10.1007/s11904-010-0071-3 PMID:21221855 [ Links ]

    16. Country and lending groups [Internet]. Washington: World Bank; 2011. Available from:[accessed 12 January 2012] [ Links ]

    17. Freeman MF, Tukey JW. Transformations related to the angular and the square root. Ann Inst Stat Math 1950;21:607-11. [ Links ]

    18. Fleiss JL. The statistical basis of meta-analysis. Stat Methods Med Res 1993;2:121-45. doi:10.1177/096228029300200202 PMID:8261254 [ Links ]

    19. Walters DE. The need for statistical rigour when pooling data from a variety of sources. Hum Reprod 2000;15:1205-6. doi:10.1093/humrep/15.5.1205 PMID:10783380 [ Links ]

    20. Rücker G, Schwarzer G, Carpenter JR, Schumacher M. Undue reliance on I(2) in assessing heterogeneity may mislead. BMC Med Res Methodol 2008;8:79. doi:10.1186/1471-2288-8-79 PMID:19036172 [ Links ]

    21. Borenstein M, Hedges L, Higgins J, Rothstein H. Meta-regression. In: Borenstein M, Hedges LV, Higgins JPT, Rothstein HR, editors. Introduction to meta-analysis. Chichester: Wiley; 2009. pp.190-202. [ Links ]

    22. El-Zayadi A, Simmonds P, Dabbous H, Prescott L, Selim O, Ahdy A. Response to interferon-alpha of Egyptian patients infected with hepatitis C virus genotype 4. J Viral Hepat 1996;3:261-4. doi:10.1111/j.1365-2893.1996.tb00052.x PMID:8914006 [ Links ]

    23. Rossignol JF, Elfert A, El-Gohary Y, Keeffe EB. Improved virologic response in chronic hepatitis C genotype 4 treated with nitazoxanide, peginterferon, and ribavirin. Gastroenterology 2009;136:856-62. doi:10.1053/j.gastro.2008.11.037 PMID:19135998 [ Links ]

    24. Jiao J, Wang JB. Hepatitis C virus genotypes, HLA-DRB alleles and their response to interferon-alpha and ribavirin in patients with chronic hepatitis C. Hepatobiliary Pancreat Dis Int 2005;4:80-3. PMID:15730926 [ Links ]

    25. Mishra PK, Bhargava A, Khan S, Pathak N, Punde RP, Varshney S. Prevalence of hepatitis C virus genotypes and impact of T helper cytokines in achieving sustained virological response during combination therapy: a study from central India. Indian J Med Microbiol 2010;28:358-62. doi:10.4103/0255-0857.71813 PMID:20966569 [ Links ]

    26. Chen JY, Lin CY, Wang CM, Lin YT, Kuo SN, Shiu CF et al. IL28B genetic variations are associated with high sustained virological response (SVR) of interferon-alpha plus ribavirin therapy in Taiwanese chronic HCV infection. Genes Immun 2011;12:300-9. doi:10.1038/gene.2011.1 PMID:21346780 [ Links ]

    27. Ahmed WU, Arif A, Qureshi H, Alam SE, Ather R, Fariha S et al. Factors influencing the response of interferon therapy in chronic hepatitis C patients. J Coll Physicians Surg Pak 2011;21:69-73. PMID:21333235 [ Links ]

    28. Akbar H, Idrees M, Butt S, Awan Z, Sabar MF, Rehaman IU et al. High baseline interleukine-8 level is an independent risk factor for the achievement of sustained virological response in chronic HCV patients. Infect Genet Evol 2011;11:1301-5. doi:10.1016/j.meegid.2011.04.021 PMID:21554996 [ Links ]

    29. Akram M, Idrees M, Zafar S, Hussain A, Butt S, Afzal S et al. Effects of host and virus related factors on interferon-alpha+ribavirin and pegylated-interferon+ribavirin treatment outcomes in chronic hepatitis C patients. Virol J 2011;8:234. doi:10.1186/1743-422X-8-234 PMID:21575275 [ Links ]

    30. Ali I, Khan S, Attaullah S, Khan SN, Khan J, Siraj S et al. Response to combination therapy of HCV 3a infected Pakistani patients and the role of NS5A protein. Virol J 2011;8:258. doi:10.1186/1743-422X-8-258 PMID:21609495 [ Links ]

    31. Ali L, Mansoor A, Ahmad N, Siddiqi S, Mazhar K, Muazzam AG et al. Patient HLA-DRB1* and -DQB1* allele and haplotype association with hepatitis C virus persistence and clearance. J Gen Virol 2010;91:1931-8. doi:10.1099/vir.0.018119-0 PMID:20392899 [ Links ]

    32. Amarapurkar D, Dhorda M, Kirpalani A, Amarapurkar A, Kankonkar S. Prevalence of hepatitis C genotypes in Indian patients and their clinical significance. J Assoc Physicians India 2001;49:983-5. PMID:11848330 [ Links ]

    33. Antaki N, Hermes A, Hadad M, Ftayeh M, Antaki F, Abdo N et al. Efficacy of interferon plus ribavirin in the treatment of hepatitis C virus genotype 5. J Viral Hepat 2008;15:383-6. doi:10.1111/j.1365-2893.2007.00946.x PMID:18086180 [ Links ]

    34. Bouzgarrou N, Hassen E, Mahfoudh W, Gabbouj S, Schvoerer E, Ben Yahia A et al. NS5A(ISDR-V3) region genetic variability of Tunisian HCV-1b strains: correlation with the response to the combined interferon/ribavirin therapy. J Med Virol 2009;81:2021-8. doi:10.1002/jmv.21641 PMID:19856481 [ Links ]

    35. Dai CY, Chuang WL, Chang WY, Chen SC, Lee LP, Hsieh MY et al. Co-infection of SENV-D among chronic hepatitis C patients treated with combination therapy with high-dose interferon-alfa and ribavirin. World J Gastroenterol 2005;11:4241-5. PMID:16015698 [ Links ]

    36. David J, Rajasekar A, Daniel HD, Ngui SL, Ramakrishna B, Zachariah UG et al. Infection with hepatitis C virus genotype 3 - experience of a tertiary health care centre in south India. Indian J Med Microbiol 2010;28:155-7. doi:10.4103/0255-0857.62495 PMID:20404464 [ Links ]

    37. El-Zayadi A, Selim O, Hamdy H, El-Tawil A, Badran HM, Attia M et al. Impact of cigarette smoking on response to interferon therapy in chronic hepatitis C Egyptian patients. World J Gastroenterol 2004;10:2963-6. PMID:15378774 [ Links ]

    38. El-Zayadi AR, Attia M, Barakat EM, Badran HM, Hamdy H, El-Tawil A et al. Response of hepatitis C genotype-4 naive patients to 24 weeks of peg-interferon-alpha2b/ribavirin or induction-dose interferon-alpha2b/ribavirin/amantadine: a non-randomized controlled study. Am J Gastroenterol 2005;100:2447-52. doi:10.1111/j.1572-0241.2005.00253.x PMID:16279899 [ Links ]

    39. Gallegos-Orozco JF, Loaeza-del Castillo A, Fuentes AP, Garcia-Sandoval M, Soto L, Rodriguez R et al. Early hepatitis C virus changes and sustained response in patients with chronic hepatitis C treated with peginterferon alpha-2b and ribavirin. Liver Int 2005;25:91-5. doi:10.1111/j.1478-3231.2005.1040.x PMID:15698404 [ Links ]

    40. Gong GZ, Lai LY, Jiang YF, He Y, Su XS. HCV replication in PBMC and its influence on interferon therapy. World J Gastroenterol 2003;9:291-4. PMID:12532451 [ Links ]

    41. Hazari S, Panda SK, Gupta SD, Batra Y, Singh R, Acharya SK. Treatment of hepatitis C virus infection in patients of northe\rn India. J Gastroenterol Hepatol 2004;19:1058-65. doi:10.1111/j.1440-1746.2004.03405.x PMID:15304125 [ Links ]

    42. Idrees M, Riazuddin S. A study of best positive predictors for sustained virologic response to interferon alpha plus ribavirin therapy in naive chronic hepatitis C patients. BMC Gastroenterol 2009;9:5. doi:10.1186/1471-230X-9-5 PMID:19152711 [ Links ]

    43. Iqbal SKU-R, Dogar MZ, Bashir S, Akhtar M. Sustained biochemical and virological response of different HCV genotypes to Interferon-alpha plus ribavirin combination therapy Pharmacologyonline 2010;2:161-9. [ Links ]

    44. Kalantari H, Kazemi F, Minakari M. Efficacy of triple therapy with interferon alpha-2b, ribavirin and amantadine in the treatment of naïve patients with chronic hepatitis C. J Res Med Sci 2007;12:178-85. [ Links ]

    45. Khalid SR, Khan AA, Alam A, Lak NH, Butt AK, Shafqat F et al. Interferon-ribavirin treatment in chronic hepatitis C - the less talked about aspects. J Ayub Med Coll Abbottabad 2009;21:99-102. PMID:20524481 [ Links ]

    46. Khan AA, Sarwar S. Response to combination therapy in hepatitis virus C genotype 2 and 3. J Coll Physicians Surg Pak 2009;19:473-7. PMID:19651007 [ Links ]

    47. Khokhar N. Effectiveness of 48 weeks interferon alfa-2b in combination with ribavirin as initial treatment of chronic hepatitis. J Ayub Med Coll Abbottabad 2002;14:5-8. PMID:12476854 [ Links ]

    48. Muhammad N, Jan MA, Rahman N. Outcome of combined interferon-ribavirin in the treatment of chronic hepatitis C. J Coll Physicians Surg Pak 2004;14:651-3. PMID:15530272 [ Links ]

    49. Petrenkiene V, Gudinaviciene I, Jonaitis L, Kupcinskas L. Interferon alpha-2b in combination with ribavirin for the treatment of chronic hepatitis C: assessment of virological, biochemical and histological treatment response. Medicina (Kaunas) 2004;40:538-46. PMID:15208476 [ Links ]

    50. Pramoolsinsap C, Poovorawan Y, Sura T, Theamboonlers A, Busagorn N, Kurathong S. Hepatitis G infection and therapeutic response to interferon in HCV-related chronic liver disease. Southeast Asian J Trop Med Public Health 1998;29:480-90. PMID:10437943 [ Links ]

    51. Qureshi S, Batool U, Iqbal M, Qureshi O, Kaleem R, Aziz H et al. Response rates to standard interferon treatment in HCV genotype 3a. J Ayub Med Coll Abbottabad 2009;21:10-4. PMID:21067014 [ Links ]

    52. Sarwar S, Butt AK, Khan AA, Alam A, Ahmad I, Dilshad A. Serum alanine aminotransferase level and response to interferon-ribavirin combination therapy in patients with chronic hepatitis C. J Coll Physicians Surg Pak 2006;16:460-3. PMID:16827956 [ Links ]

    53. Sarwar STS. Treatment failure in chronic hepatitis C: predictors other than viral kinetics. Rawal Med J 2010;35:217-20. [ Links ]

    54. Schiavon LL, Narciso-Schiavon JL, Carvalho-Filho RJ, Sampaio JP, El Batah PN, Silva GA et al. Evidence of a significant role for fast-mediated apoptosis in HCV clearance during pegylated interferon plus ribavirin combination therapy. Antivir Ther 2011;16:291-8. doi:10.3851/IMP1768 PMID:21555811 [ Links ]

    55. Shaker OG, Eskander EF, Yahya SM, Mohamed MS, Abd-Rabou AA. Genetic variation in BCL-2 and response to interferon in hepatitis C virus type 4 patients. Clin Chim Acta 2011;412:593-8. doi:10.1016/j.cca.2010.12.009 PMID:21159314 [ Links ]

    56. Shen C, Hu T, Shen L, Gao L, Xie W, Zhang J. Mutations in ISDR of NS5A gene influence interferon efficacy in Chinese patients with chronic hepatitis C virus genotype 1b infection. J Gastroenterol Hepatol 2007;22:1898-903. doi:10.1111/j.1440-1746.2006.04566.x PMID:17914967 [ Links ]

    57. Sixtos-Alonso MS, Sanchez-Munoz F, Sanchez-Avila JF, Martinez RA, Dominguez Lopez A, Vargas Vorackova F et al. IFN-stimulated gene expression is a useful potential molecular marker of response to antiviral treatment with Peg-IFNalpha 2b and ribavirin in patients with hepatitis C virus genotype 1. Arch Med Res 2011;42:28-33. doi:10.1016/j.arcmed.2011.01.001 PMID:21376259 [ Links ]

    58. Sood A, Midha V, Sood N, Awasthi G. Chronic hepatitis C - treatment results in northern India. Trop Gastroenterol 2002;23:172-5. PMID:12833703 [ Links ]

    59. Stefano JT, Correa-Giannella ML, Ribeiro CM, Alves VA, Massarollo PC, Machado MC et al. Increased hepatic expression of insulin-like growth factor-I receptor in chronic hepatitis C. World J Gastroenterol 2006;12:3821-8. PMID:16804965 [ Links ]

    60. Suresh RL, Kananathan R, Merican I. Chronic hepatitis C - a study of 105 cases between 1990-2000. Med J Malaysia 2001;56:243-7. PMID:11771088 [ Links ]

    61. Szanto P, Grigorescu M, Dumitru I, Serban A. Steatosis in hepatitis C virus infection. Response to anti-viral therapy. J Gastrointestin Liver Dis 2006;15:117-24. PMID:16802005 [ Links ]

    62. Zuberi BF, Zuberi FF, Memon SA, Qureshi MH, Ali SZ, Afsar S. Sustained virological response based on rapid virological response in genotype-3 chronic hepatitis C treated with standard interferon in the Pakistani population. World J Gastroenterol 2008;14:2218-21. doi:10.3748/wjg.14.2218 PMID:18407597 [ Links ]

    63. Carneiro MV, Souza FF, Teixeira AC, Figueiredo JF, Villanova MG, Secaf M et al. The H63D genetic variant of the HFE gene is independently associated with the virological response to interferon and ribavirin therapy in chronic hepatitis C. Eur J Gastroenterol Hepatol 2010;22:1204-10. doi:10.1097/MEG.0b013e32833bec1e PMID:20555268 [ Links ]

    64. Barone AA, Tosta RA, Tengan FM, Marins JH, Cavalheiro Nde P, Cardi BA. Are anti-interferon antibodies the cause of failure in chronic HCV hepatitis treatment? Braz J Infect Dis 2004;8:10-7. doi:10.1590/S1413-86702004000100002 PMID:15286876 [ Links ]

    65. Carneiro VL, Lemaire DC, Bendicho MT, Souza SL, Cavalcante LN, Angelo AL et al. Natural killer cell receptor and HLA-C gene polymorphisms among patients with hepatitis C: a comparison between sustained virological responders and non-responders. Liver Int 2010;30:567-73. doi:10.1111/j.1478-3231.2010.02212.x PMID:20456039 [ Links ]

    66. Kumar D, Malik A, Asim M, Chakravarti A, Das RH, Kar P. Response of combination therapy on viral load and disease severity in chronic hepatitis C. Dig Dis Sci 2008;53:1107-13. doi:10.1007/s10620-007-9960-8 PMID:17934834 [ Links ]

    67. Vigani AG, Macedo de Oliveira A, Tozzo R, Pavan MH, Goncales ES, Fais V et al. The association of cryoglobulinaemia with sustained virological response in patients with chronic hepatitis C. J Viral Hepat 2011;18:e91-8. doi:10.1111/j.1365-2893.2010.01385.x PMID:20969676 [ Links ]

    68. Villela-Nogueira CA, Perez RM, de Segadas Soares JA, Coelho HS. Gamma-glutamyl transferase (GGT) as an independent predictive factor of sustained virologic response in patients with hepatitis C treated with interferon-alpha and ribavirin. J Clin Gastroenterol 2005;39:728-30. doi:10.1097/01.mcg.0000174025.19214.32 PMID:16082285 [ Links ]

    69. Parise ER, de Oliveira AC, Conceicao RD, Amaral AC, Leite K. Response to treatment with interferon-alpha and ribavirin in patients with chronic hepatitis C virus genotypes 2 and 3 depends on the degree of hepatic fibrosis. Braz J Infect Dis 2006;10:78-81. doi:10.1590/S1413-86702006000200002 PMID:16878256 [ Links ]

    70. Cheinquer N, Cheinquer H, Wolff FH, Coelho-Borges S. Effect of sustained virologic response on the incidence of hepatocellular carcinoma in patients with HCV cirrhosis. Braz J Infect Dis 2010;14:457-61. doi:10.1590/S1413-86702010000500006 PMID:21221473 [ Links ]

    71. Gupta R, Ramakrishna CH, Lakhtakia S, Tandan M, Banerjee R, Reddy DN. Efficacy of low dose peginterferon alpha-2b with ribavirin on chronic hepatitis C. World J Gastroenterol 2006;12:5554-6. PMID:17006999 [ Links ]

    72. Liao XW, Ling Y, Li XH, Han Y, Zhang SY, Gu LL et al. Association of genetic variation in IL28B with hepatitis C treatment-induced viral clearance in the Chinese Han population. Antivir Ther 2011;16:141-7. doi:10.3851/IMP1703 PMID:21447862 [ Links ]

    73. Araújo ES, Dahari H, Neumann AU, de Paula Cavalheiro N, Melo CE, de Melo ES et al. Very early prediction of response to HCV treatment with PEG-IFN-alfa-2a and ribavirin in HIV/HCV-coinfected patients. J Viral Hepat 2011;18:e52-60. doi:10.1111/j.1365-2893.2010.01358.x PMID:20738775 [ Links ]

    74. Aziz H, Gil ML, Waheed Y, Adeeb U, Raza A, Bilal I et al. Evaluation of prognostic factors for peg interferon alfa-2b plus ribavirin treatment on HCV infected patients in Pakistan. Infect Genet Evol 2011;11:640-5. doi:10.1016/j.meegid.2011.01.022 PMID:21316487 [ Links ]

    75. Butt AS, Mumtaz K, Aqeel I, Shah HA, Hamid S, Jafri W. Sustained virological response to pegylated interferon and ribavirin in patients with genotype 3 HCV cirrhosis. Trop Gastroenterol 2009;30:207-12. PMID:20426280 [ Links ]

    76. de Almeida PR, de Mattos AA, Amaral KM, Feltrin AA, Zamin P, Tovo CV et al. Treatment of hepatitis C with peginterferon and ribavirin in a public health program. Hepatogastroenterology 2009;56:223-6. PMID:19453062 [ Links ]

    77. Esmat G, Fattah SA. Evaluation of a novel pegylated interferon alpha-2a (Reiferon Retard®) in Egyptian patients with chronic hepatitis C - genotype 4. Digest Liver Dis Suppl 2009;;3:17-9. [ Links ]

    78. Gonçales FL Jr, Vigani A, Goncales N, Barone AA, Araujo E, Focaccia R et al. Weight-based combination therapy with peginterferon alpha-2b and ribavirin for naive, relapser and non-responder patients with chronic hepatitis C. Braz J Infect Dis 2006;10:311-6. PMID:17293917 [ Links ]

    79. Males S, Gad RR, Esmat G, Abobakr H, Anwar M, Rekacewicz C et al. Serum alpha-foetoprotein level predicts treatment outcome in chronic hepatitis C. Antivir Ther 2007;12:797-803. PMID:17713163 [ Links ]

    80. Narciso-Schiavon JL, Freire FC, Suarez MM, Ferrari MV, Scanhola GQ, de Lucca Schiavon L et al. Antinuclear antibody positivity in patients with chronic hepatitis C: clinically relevant or an epiphenomenon? Eur J Gastroenterol Hepatol 2009;21:440-6. doi:10.1097/MEG.0b013e3283089392 PMID:19382301 [ Links ]

    81. Narciso-Schiavon JL, de Lucca Schiavon L, Carvalho-Filho RJ, Sampaio JP, Batah PN, Barbosa DV et al. Gender influence on treatment of chronic hepatitis C genotype 1. Rev Soc Bras Med Trop 2010;43:217-23. doi:10.1590/S0037-86822010000300001 PMID:20563484 [ Links ]

    82. Parise ER, de Oliveira AC, Ferraz ML, Pereira AB, Leite KR. Cryoglobulinemia in chronic hepatitis C: clinical aspects and response to treatment with interferon alpha and ribavirin. Rev Inst Med Trop Sao Paulo 2007;49:67-72. doi:10.1590/S0036-46652007000200001 PMID:17505661 [ Links ]

    83. Pereira PS, Silva IS, Uehara SN, Emori CT, Lanzoni VP, Silva AE et al. Chronic hepatitis C: hepatic iron content does not correlate with response to antiviral therapy. Rev Inst Med Trop Sao Paulo 2009;51:331-6. PMID:20209268 [ Links ]

    84. Ray G, Pal S, Nayyar I, Dey S. Efficacy and tolerability of pegylated interferon alpha 2b and ribavirin in chronic hepatitis C - a report from eastern India. Trop Gastroenterol 2007;28:109-12. PMID:18383998 [ Links ]

    85. Rossignol JF, Elfert A, Keeffe EB. Treatment of chronic hepatitis C using a 4-week lead-in with nitazoxanide before peginterferon plus nitazoxanide. J Clin Gastroenterol 2010;44:504-9. PMID:20048684 [ Links ]

    86. Silva GF, Polonio RJ, Pardini MI, Corvino SM, Henriques RM, Peres MN et al. Using pegylated interferon alfa-2b and ribavirin to treat chronic hepatitis patients infected with hepatitis C virus genotype 1: are nonresponders and relapsers different populations? Braz J Infect Dis 2007;11:554-60. doi:10.1590/S1413-86702007000600006 PMID:18327466 [ Links ]

    87. Sood A, Midha V, Sood N, Bansal M. Pegylated interferon alfa 2b and oral ribavirin in patients with HCV-related cirrhosis. Indian J Gastroenterol 2006;25:283-5. PMID:17264426 [ Links ]

    88. Taha AA, El-Ray A, El-Ghannam M, Mounir B. Efficacy and safety of a novel pegylated interferon alpha-2a in Egyptian patients with genotype 4 chronic hepatitis C. Can J Gastroenterol 2010;24:597-602. PMID:21037988 [ Links ]

    89. Tohra SK, Taneja S, Ghosh S, Sharma BK, Duseja A, Dhiman RK et al. Prediction of sustained virological response to combination therapy with pegylated interferon alfa and ribavirin in patients with genotype 3 chronic hepatitis C. Dig Dis Sci 2011;56:2449-55. doi:10.1007/s10620-011-1770-3 PMID:21706207 [ Links ]

    90. Lerias de Almeida PR, Alves de Mattos A, Valle Tovo C. Sustained virological response according to the type of early virological response in HCV and HCV/HIV. Ann Hepatol 2010;9:150-5. PMID:20526007 [ Links ]

    91. Khattab M, Eslam M, Sharwae MA, Shatat M, Ali A, Hamdy L. Insulin resistance predicts rapid virologic response to peginterferon/ribavirin combination therapy in hepatitis C genotype 4 patients. Am J Gastroenterol 2010;105:1970-7. doi:10.1038/ajg.2010.110 PMID:20234345 [ Links ]

    92. El Makhzangy H, Esmat G, Said M, Elraziky M, Shouman S, Refai R et al. Response to pegylated interferon alfa-2a and ribavirin in chronic hepatitis C genotype 4. J Med Virol 2009;81:1576-83. doi:10.1002/jmv.21570 PMID:19626613 [ Links ]

    93. Bader el-Din NG, Abd el-Meguid M, Tabll AA, Anany MA, Esmat G, Zayed N et al. Human cytomegalovirus infection inhibits response of chronic hepatitis-C-virus-infected patients to interferon-based therapy. J Gastroenterol Hepatol 2011;26:55-62. doi:10.1111/j.1440-1746.2010.06319.x PMID:21175794 [ Links ]

    94. Shaker O, Ahmed A, Doss W, Abdel-Hamid M. MxA expression as marker for assessing the therapeutic response in HCV genotype 4 Egyptian patients. J Viral Hepat 2010;17:794-9. doi:10.1111/j.1365-2893.2009.01241.x PMID:20002306 [ Links ]

    95. Belhadj N, Houissa F, Elloumi H, Ouakaa A, Gargouri D, Romani M et al. Virological response of Tunisians patients treated by peginterferon plus ribavirin for chronic hepatitis C: a preliminary study. Tunis Med 2008;86:341-5. PMID:19476135 [ Links ]

    96. Chuang JY, Yang SS, Lu YT, Hsieh YY, Chen CY, Chang SC et al. IL-10 promoter gene polymorphisms and sustained response to combination therapy in Taiwanese chronic hepatitis C patients. Dig Liver Dis 2009;41:424-30. doi:10.1016/j.dld.2008.09.017 PMID:19004675 [ Links ]

    97. Gao DY, Zhang XX, Hou G, Jin GD, Deng Q, Kong XF et al. Assessment of specific antibodies to F protein in serum samples from Chinese hepatitis C patients treated with interferon plus ribavirin. J Clin Microbiol 2008;46:3746-51. doi:10.1128/JCM.00612-08 PMID:18832124 [ Links ]

    98. Gheorghe L, Grigorescu M, Iacob S, Damian D, Gheorghe C, Iacob R et al. Effectiveness and tolerability of pegylated Interferon alpha-2a and ribavirin combination therapy in Romanian patients with chronic hepatitis C: from clinical trials to clinical practice. Rom J Gastroenterol 2005;14:109-15. PMID:15990928 [ Links ]

    99. Gheorghe L, Iacob S, Grigorescu M, Sporea I, Sirli R, Damian D et al. High sustained virological response rate to combination therapy in genotype 1 patients with histologically mild hepatitis C. J Gastrointestin Liver Dis 2009;18:51-6. PMID:19337634 [ Links ]

    100. Gheorghe L, Iacob S, Sporea I, Grigorescu M, Sirli R, Damian D et al. Efficacy, tolerability and predictive factors for early and sustained virologic response in patients treated with weight-based dosing regimen of PegIFN alpha-2b ribavirin in real-life healthcare setting. J Gastrointestin Liver Dis 2007;16:23-9. PMID:17410285 [ Links ]

    101. Ibrahim M, Gomaa W, Ibrahim Y, El Hadad H, Shatat M, Aleem AA et al. Nitric oxide levels and sustained virological response to pegylated-interferon alpha2a plus ribavirin in chronic HCV genotype 4 hepatitis: a prospective study. J Gastrointestin Liver Dis 2010;19:387-92. PMID:21188329 [ Links ]

    102. Jabbari H, Bayatian A, Sharifi AH, Zaer-Rezaee H, Fakharzadeh E, Asadi R et al. Safety and efficacy of locally manufactured pegylated interferon in hepatitis C patients. Arch Iran Med 2010;13:306-12. PMID:20597564 [ Links ]

    103. Kumthip K, Pantip C, Chusri P, Thongsawat S, O'Brien A, Nelson KE et al. Correlation between mutations in the core and NS5A genes of hepatitis C virus genotypes 1a, 1b, 3a, 3b, 6f and the response to pegylated interferon and ribavirin combination therapy. J Viral Hepat 2011;18:e117-25. doi:10.1111/j.1365-2893.2010.01379.x PMID:20955493 [ Links ]

    104. Laufer N, Bolcic F, Rolon MJ, Martinez A, Reynoso R, Perez H et al. HCV RNA decline in the first 24 h exhibits high negative predictive value of sustained virologic response in HIV/HCV genotype 1 co-infected patients treated with peginterferon and ribavirin. Antiviral Res 2011;90:92-7. doi:10.1016/j.antiviral.2011.02.013 PMID:21376083 [ Links ]

    105. Njouom R, Sartre MT, Timba I, Nerrienet E, Tchendjou P, Pasquier C et al. Efficacy and safety of peginterferon alpha-2a/ribavirin in treatment-naive Cameroonian patients with chronic hepatitis C. J Med Virol 2008;80:2079-85. doi:10.1002/jmv.21319 PMID:19040282 [ Links ]

    106. Ridruejo E, Adrover R, Cocozzella D, Fernandez N, Reggiardo MV. Efficacy, tolerability and safety in the treatment of chronic hepatitis C with combination of peg-interferon - ribavirin in daily practice. Ann Hepatol 2010;9:46-51. PMID:20308722 [ Links ]

    107. Seow EL, Robert Ding PH. Pegylated interferon alfa-2b (peg-intron) plus ribavirin (rebetol) in the treatment of chronic hepatitis C: a local experience. Med J Malaysia 2005;60:637-41. PMID:16515116 [ Links ]

    108. Sombie RBA, Somda S, Sangare L, Lompo O, Kabore Z, Tieno H et al. Chronic hepatitis C: epidemiology, diagnosis and treatment in Yalgado-Ouedraogo teaching hospital in Ouagadougou. J Afr Hepato Gastroenterol 2011;5:5-16. [ Links ]

    109. Sporea I, Sirli R, Curescu M, Gheorghe L, Popescu A, Bota S et al. Outcome of antiviral treatment in patients with chronic genotype 1 HCV hepatitis: a retrospective study in 507 patients. J Gastrointestin Liver Dis 2010;19:261-4. PMID:20922189 [ Links ]

    110. Su WP,, Peng CY, Lai HC, Liao KF, Huang WH, Chuang PH et al. Persistent transaminase elevations in chronic hepatitis C patients with virological response during peginterferon and ribavirin therapy. Hepatogastroenterology 2009;56:798-801. [ Links ]

    111. Yu JW, Sun LJ, Zhao YH, Kang P, Gao J, Li SC. Analysis of the efficacy of treatment with peginterferon alpha-2a and ribavirin in patients coinfected with hepatitis B virus and hepatitis C virus. Liver Int 2009;29:1485-93. doi:10.1111/j.1478-3231.2009.02080.x PMID:19602134 [ Links ]

    112. Yu JW, Wang GQ, Sun LJ, Li XG, Li SC. Predictive value of rapid virological response and early virological response on sustained virological response in HCV patients treated with pegylated interferon alpha-2a and ribavirin. J Gastroenterol Hepatol 2007;22:832-6. doi:10.1111/j.1440-1746.2007.04904.x PMID:17565637 [ Links ]

    113. Zhou YQ, Wang XH, Hong GH, Zhu Y, Zhang XQ, Hu YJ et al. Twenty-four weeks of pegylated interferon plus ribavirin effectively treat patients with HCV genotype 6a. J Viral Hepat 2011;18:595-600. doi:10.1111/j.1365-2893.2010.01373.x PMID:21105968 [ Links ]

    114. de Segadas-Soares JA, Villela-Nogueira CA, Perez RM, Nabuco LC, Brandao-Mello CE, Coelho HS. Is the rapid virologic response a positive predictive factor of sustained virologic response in all pretreatment status genotype 1 hepatitis C patients treated with peginterferon-alpha2b and ribavirin? J Clin Gastroenterol 2009;43:362-6. doi:10.1097/MCG.0b013e3181775e6a PMID:19077732 [ Links ]

    115. Jovanović M, Jovanović B, Potic M, Konstantinović L, Vrbic M, Radovanovic-Dinic B et al. Characteristics of chronic hepatitis C among intravenous drug users: a comparative analysis. Bosn J Basic Med Sci 2010;10:153-7. PMID:20507297 [ Links ]

    116. Awad T, Thorlund K, Hauser G, Stimac D, Mabrouk M, Gluud C. Peginterferon alpha-2a is associated with higher sustained virological response than peginterferon alfa-2b in chronic hepatitis C: systematic review of randomized trials. Hepatology 2010;51:1176-84. doi:10.1002/hep.23504 PMID:20187106 [ Links ]

    117. Swan T. The hepatitis C treatment pipeline report. New York: Treatment Action Group; 2011. Available from: [accessed 12 January 2012] [ Links ]

    118. Orenstein EW, Basu S, Shah NS, Andrews JR, Friedland GH, Moll AP et al. Treatment outcomes among patients with multidrug-resistant tuberculosis: systematic review and meta-analysis. Lancet Infect Dis 2009;9:153-61. doi:10.1016/S1473-3099(09)70041-6 PMID:19246019 [ Links ]

    119. Hofmann WP, Zeuzem S. A new standard of care for the treatment of chronic HCV infection. Nat Rev Gastroenterol Hepatol 2011;8:257-64. PMID:21468124 [ Links ]

    120. Opar A. Excitement grows for potential revolution in hepatitis C virus treatment. Nat Rev Drug Discov 2010;9:501-3. doi:10.1038/nrd3214 PMID:20592732 [ Links ]